Kellie N. Smith
Cited by
Cited by
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
Neoadjuvant PD-1 blockade in resectable lung cancer
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer
V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ...
Cancer discovery 7 (3), 264-276, 2017
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ...
Annals of Oncology 29 (8), 1853-1860, 2018
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ...
Nature 596 (7870), 126-132, 2021
Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer
V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ...
Cancer research 79 (6), 1214-1225, 2019
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
V Anagnostou, N Niknafs, K Marrone, DC Bruhm, JR White, J Naidoo, ...
Nature cancer 1 (1), 99-111, 2020
The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity
L Danilova, V Anagnostou, JX Caushi, JW Sidhom, H Guo, HY Chan, ...
Cancer immunology research 6 (8), 888-899, 2018
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
JE Reuss, V Anagnostou, TR Cottrell, KN Smith, F Verde, M Zahurak, ...
Journal for immunotherapy of cancer 8 (2), 2020
Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis
F Housseau, S Wu, EC Wick, H Fan, X Wu, NJ Llosa, KN Smith, A Tam, ...
Cancer research 76 (8), 2115-2124, 2016
Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non–small cell lung cancer
J Zhang, Z Ji, JX Caushi, M El Asmar, V Anagnostou, TR Cottrell, ...
Clinical Cancer Research 26 (6), 1327-1337, 2020
Metabolic programs define dysfunctional immune responses in severe COVID-19 patients
EA Thompson, K Cascino, AA Ordonez, W Zhou, A Vaghasia, ...
Cell reports 34 (11), 2021
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
PM Forde, V Anagnostou, Z Sun, SE Dahlberg, HL Kindler, N Niknafs, ...
Nature medicine 27 (11), 1910-1920, 2021
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses
AG Dykema, B Zhang, BA Woldemeskel, CC Garliss, LS Cheung, ...
The Journal of clinical investigation 131 (10), 2021
Persistent mutation burden drives sustained anti-tumor immune responses
N Niknafs, A Balan, C Cherry, K Hummelink, K Monkhorst, XM Shao, ...
Nature medicine 29 (2), 440-449, 2023
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
M Hwang, JV Canzoniero, S Rosner, G Zhang, JR White, Z Belcaid, ...
Journal for immunotherapy of cancer 10 (6), 2022
Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors
NJ Llosa, B Luber, AJ Tam, KN Smith, N Siegel, AH Awan, H Fan, T Oke, ...
Clinical Cancer Research 25 (17), 5250-5259, 2019
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
NG LaRocca, LD Hudson, R Rudick, D Amtmann, L Balcer, R Benedict, ...
Multiple Sclerosis Journal 24 (11), 1469-1484, 2018
Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy
SL Topalian, PM Forde, LA Emens, M Yarchoan, KN Smith, DM Pardoll
Cancer cell 41 (9), 1551-1566, 2023
Selective Induction of CTL Helper Rather Than Killer Activity by Natural Epitope Variants Promotes Dendritic Cell–Mediated HIV-1 Dissemination
RB Mailliard, KN Smith, RJ Fecek, G Rappocciolo, EJM Nascimento, ...
The Journal of Immunology 191 (5), 2570-2580, 2013
The system can't perform the operation now. Try again later.
Articles 1–20